Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$152.55 USD

152.55
15,971,296

+3.56 (2.39%)

Updated Aug 21, 2026 04:01 PM ET

After-Market: $153.51 +0.96 (0.63%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (160 out of 247)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study

by Zacks Equity Research

Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.

Ahan Chakraborty headshot

Will LLY's Oncology Portfolio Provide Key Diversification Benefits?

by Ahan Chakraborty

Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.

Kanishka Das headshot

Will Merck's Cost Cuts and New Drug Approvals Ease Headwinds?

by Kanishka Das

MRK expects strong Keytruda sales, new drug launches and $3B in planned cost savings to offset pressure from declining Gardasil sales and other headwinds.

Kinjel Shah headshot

J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?

by Kinjel Shah

ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.

Kanishka Das headshot

MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline

by Kanishka Das

Merck advances growth with phase III pipeline backed by positive data for its potential first oral PCSK9 inhibitor.

Kinjel Shah headshot

J&J Gears Up for Some Key New Drug Approvals and Launches

by Kinjel Shah

JNJ believes 10 of its new products and pipeline candidates can deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta and others.

Ekta Bagri headshot

Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?

by Ekta Bagri

Bristol Myers expects mid to high-single-digit sales growth for Opdivo and Qvantig in 2025 as approvals and launches gain momentum.

Kanishka Das headshot

Can Korlym Drive Corcept's Growth Through the Rest of 2025?

by Kanishka Das

CORT projects $850-$900M in 2025 revenues as Korlym sales rise and relacorilant nears an FDA decision for Cushing's syndrome.

Kinjel Shah headshot

ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?

by Kinjel Shah

AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.

Zacks Equity Research

Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.